Delving into the Latest Updates on FTL-001 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

4-1BB

Mechanism

4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Sound Biopharmaceuticals Ltd.

Active Organization

Sound Biopharmaceuticals Ltd.

Chime Biologics Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的是评价FTL001在晚期复发转移和难治性实体瘤受试者中的安全性和耐受性。次要目的包括评价 FTL001的初步抗肿瘤活性、药代动力学（PK）特征和免疫原性等。探索目的包括探索FTL001的药效学特征、相关生物标志物与抗肿瘤疗效的关系等。

[Translation]

The primary objective is to evaluate the safety and tolerability of FTL001 in subjects with advanced recurrent metastatic and refractory solid tumors. Secondary objectives include evaluating the preliminary anti-tumor activity, pharmacokinetic (PK) characteristics and immunogenicity of FTL001. Exploratory objectives include exploring the pharmacodynamic characteristics of FTL001, the relationship between relevant biomarkers and anti-tumor efficacy, etc.

Start Date16 May 2023

Sponsor / Collaborator

Sound Biopharmaceuticals Ltd.

[+1]

100 Clinical Results associated with FTL-001

Login to view more data

100 Translational Medicine associated with FTL-001

Login to view more data

100 Patents (Medical) associated with FTL-001

Login to view more data

100 Deals associated with FTL-001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Sound Biopharmaceuticals Ltd.	16 May 2023
Advanced Malignant Solid Neoplasm	Phase 1	CN	Chime Biologics Ltd.	16 May 2023